Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TCT9
UPID:
HM13_HUMAN
Alternative names:
Intramembrane protease 1; Presenilin-like protein 3; Signal peptide peptidase
Alternative UPACC:
Q8TCT9; B2RAY5; E1P5L3; Q15K36; Q540H8; Q5JWP2; Q5JWP3; Q5JWP4; Q5JWP5; Q7Z4F2; Q86Y35; Q95H87; Q9H110; Q9H111
Background:
Minor histocompatibility antigen H13, also known as Intramembrane protease 1, Presenilin-like protein 3, and Signal peptide peptidase, plays a crucial role in intramembrane proteolysis of signal peptides. This process is essential for the release of peptide fragments into the cytoplasm, generating lymphocyte cell surface epitopes and facilitating the removal of signal peptides from various proteins, including those of the hepatitis C virus.
Therapeutic significance:
Understanding the role of Minor histocompatibility antigen H13 could open doors to potential therapeutic strategies.